Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient

Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060

This is an open-label, long term compassionate use study of 125 mg per day of azimilide 2HCl in a patient who completed two other protocols (2000098 and 2001060.

Inclusion Criteria:

• No inclusion criteria as the patient to be included is this compassionate use protocol is currently receiving azimilide therapy

Exclusion Criteria:

• Currently taking Class I or other Class III antiarrhythmic drug or other drugs that may prolong QT interval.
• Is unwilling or unable to give or understand informed consent.